CODX Stock Price | Co-Diagnostics, Inc. Common Stock P/E, Revenue, EPS, & Forecasts

Co-Diagnostics, Inc. Common Stock • CODX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Co-Diagnostics, Inc. Common Stock

Ticker

CODX

Trading on

NASDAQ

ISIN

US1897631057

Industry

Medical Devices

Sector

Healthcare

CEO

Dwight H. Egan

Headquarters

2401 S. Foothill Dr., Salt Lake City, UT, United States, 84109

Employees

132

Website

https://co-dx.com

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Metrics

BasicAdvanced

Market cap

$3.7M

P/E ratio

EPS

-$29.40

Dividend Yield

0.00%

Beta

1.4

Forward P/E ratio

EBIDTA

$-34.3M

Ex dividend date

Price & volume

Market cap

$3.7M

Average daily volume

3.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

7.22

Price to book

0.14

Earnings

EPS

-$29.40

EPS estimate (current quarter)

-$0.19

EPS estimate (next quarter)

-$0.16

EBITDA

$-34.3M

Revenues (TTM)

$0.5M

Revenues per share (TTM)

$0.46

Technicals

Beta

1.4

52-week High

$46.50

52-week Low

$1.66

50-day moving average

$2.78

200-day moving average

$8.03

Short ratio

0.23

Short %

2.86%

Management effectiveness

ROE (TTM)

-62.12%

ROA (TTM)

-37.92%

Profit margin

0.00%

Gross profit margin

$0.2M

Operating margin

-4,824.49%

Growth

Quarterly earnings growth (YoY)

30.80%

Quarterly revenue growth (YoY)

-77.30%

Share stats

Outstanding Shares

2.1M

Float

1.9M

Insiders %

5.77%

Institutions %

12.26%

Analyst Insights & forecasts

50% Buy

50% Hold

0% Sell

Based on information from 2 analysts.

Average price target

$45.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.38

-$0.34

-11.12%

Q4 • 24Missed

-$0.26

-$0.33

22.00%

Q1 • 25Beat

-$0.23

-$0.66

65.15%

Q2 • 25Beat

-$0.16

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.2M

$-7.7M

-4,745.02%

Q2 • 25

$0.1M

$-5.9M

-4,049.27%

Q3 • 25

-10.76%

-23.85%

-14.66%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$46.5M

$5.3M

11.47%

Q2 • 25

$44.7M

$4.9M

10.98%

Q3 • 25

-3.71%

-7.79%

-4.23%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-8.3M

$17.1M

$0.4M

$-8.7M

Q2 • 25

$-5.9M

$2.2M

$4.1M

$-6M

Q3 • 25

-28.76%

-87.26%

846.03%

-31.18%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Co-Diagnostics, Inc. Common Stock share?

Co-Diagnostics, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Co-Diagnostics, Inc. Common Stock have?

Co-Diagnostics, Inc. Common Stock currently has 2.1M shares.

Does Co-Diagnostics, Inc. Common Stock pay dividends?

No, Co-Diagnostics, Inc. Common Stock doesn't pay dividends.

What is Co-Diagnostics, Inc. Common Stock 52 week high?

Co-Diagnostics, Inc. Common Stock 52 week high is $46.50.

What is Co-Diagnostics, Inc. Common Stock 52 week low?

Co-Diagnostics, Inc. Common Stock 52 week low is $1.66.

What is the 200-day moving average of Co-Diagnostics, Inc. Common Stock?

Co-Diagnostics, Inc. Common Stock 200-day moving average is $8.03.

Who is Co-Diagnostics, Inc. Common Stock CEO?

The CEO of Co-Diagnostics, Inc. Common Stock is Dwight H. Egan.

How many employees Co-Diagnostics, Inc. Common Stock has?

Co-Diagnostics, Inc. Common Stock has 132 employees.

What is the market cap of Co-Diagnostics, Inc. Common Stock?

The market cap of Co-Diagnostics, Inc. Common Stock is $3.7M.

What is the P/E of Co-Diagnostics, Inc. Common Stock?

The current P/E of Co-Diagnostics, Inc. Common Stock is null.

What is the EPS of Co-Diagnostics, Inc. Common Stock?

The EPS of Co-Diagnostics, Inc. Common Stock is -$29.40.

What is the PEG Ratio of Co-Diagnostics, Inc. Common Stock?

The PEG Ratio of Co-Diagnostics, Inc. Common Stock is 0.

What do analysts say about Co-Diagnostics, Inc. Common Stock?

According to the analysts Co-Diagnostics, Inc. Common Stock is considered a buy.